Menu Search
Equities

Blueprint Medicines Corp

BPMC:NSQ

Blueprint Medicines Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)96.62
  • Today's Change1.81 / 1.91%
  • Shares traded778.93k
  • 1 Year change+45.73%
  • Beta0.5809
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform7
Hold5
Sell0
Strong Sell1

Share price forecast in USD

The 19 analysts offering 12 month price targets for Blueprint Medicines Corp have a median target of 130.00, with a high estimate of 167.00 and a low estimate of 81.00. The median estimate represents a 34.55% increase from the last price of 96.62.
High72.8%167.00
Med34.5%130.00
Low-16.2%81.00

Earnings history & estimates in USD

On Oct 30, 2024, Blueprint Medicines Corp reported 3rd quarter 2024 losses of -0.89 per share. This result exceeded the -0.97 consensus loss of the 18 analysts covering the company and exceeded last year's 3rd quarter results by 59.55%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+3.01%
Blueprint Medicines Corp reported annual 2023 losses of -8.37 per share on Feb 15, 2024.
Average growth rate+12.78%
More ▼

Revenue history & estimates in USD

Blueprint Medicines Corporation had 3rd quarter 2024 revenues of 128.18m. This bettered the 127.03m consensus of the 18 analysts covering the company. This was 102.54% above the prior year's 3rd quarter results.
Average growth rate+24.33%
Blueprint Medicines Corporation had revenues for the full year 2023 of 249.38m. This was 22.22% above the prior year's results.
Average growth rate+262.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.